Y. Jansen

发表

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

B. Neyns, B. Bravenboer, B. Velkeniers, 2016, The Journal of clinical endocrinology and metabolism.

A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases

B. Neyns, B. Engels, G. Delvaux, 2015, Case reports in oncological medicine.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

R. Dummer, E. Rozeman, H. Schmidt, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

P. Ascierto, E. D. de Vries, Douglas B. Johnson, 2021, European journal of cancer.

A Comprehensive Review on the Surgical Aspect of Lung Transplant Models in Mice and Rats

M. Carlon, J. Kaes, B. Vanaudenaerde, 2022, Cells.

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab

B. Neyns, P. van Dam, M. Keyaerts, 2021, Cancers.

Anti-PD-1: When to Stop Treatment

B. Neyns, A. V. D. van der Veldt, G. Awada, 2022, Current Oncology Reports.

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

B. Neyns, P. van Dam, C. Heirman, 2020, Cancer Immunology and Immunotherapy.

Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.

B. Neyns, V. del Marmol, R. Van den Begin, 2019, Melanoma research.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

R. Dummer, E. Rozeman, H. Schmidt, 2019 .

Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO)

E. Rozeman, C. Blank, H. Schmidt, 2016 .

Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy.

S. Ong, S. Warren, B. Neyns, 2020 .

Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab

B. Neyns, M. Keyaerts, H. Everaert, 2018, Annals of Oncology.

3328 A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases

B. Neyns, C. Heirman, K. Thielemans, 2015 .

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy

B. Neyns, V. del Marmol, H. El Housni, 2018, Melanoma research.

A Focused Review on Primary Graft Dysfunction after Clinical Lung Transplantation: A Multilevel Syndrome

G. Verleden, J. Kaes, B. Vanaudenaerde, 2022, Cells.

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

Bart Neyns, B. Neyns, Simon Planken, 2017, The Lancet. Oncology.

Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.

B. Neyns, P. Janssens, A. Hoorens, 2015, Melanoma research.

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial

K. Willard-Gallo, B. Neyns, P. Kristanto, 2022, Cancers.

Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure

B. Neyns, V. del Marmol, S. Wilgenhof, 2015, Melanoma research.

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients

B. Neyns, P. Coulie, V. del Marmol, 2016, Journal of Translational Medicine.

Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases

B. Neyns, P. van Dam, G. Verset, 2019, ESMO Open.

Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse

B. Neyns, J. de Mey, I. Willekens, 2021, Cancers.

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

B. Neyns, R. Buyl, S. Wilgenhof, 2016, Journal of Translational Medicine.

Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma

B. Neyns, S. Wilgenhof, G. Meersseman, 2016, Melanoma research.

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

B. Neyns, V. del Marmol, M. Keyaerts, 2019, Journal of Translational Medicine.

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.

S. Rorive, B. Neyns, V. del Marmol, 2015, Melanoma research.

Predicting aesthetic outcome of the Nuss procedure in patients with pectus excavatum.

J. Maessen, C. Slump, E. D. de Loos, 2022, Seminars in thoracic and cardiovascular surgery.

Pembrolizumab for the treatment of uveal melanoma: A case series

B. Neyns, T. Seremet, Y. Jansen, 2020, Rare tumors.